Molecular markers in the diagnosis and staging of breast cancer.
Considerable advances have been made in understanding the molecular events that accompany the development of breast cancer. Although our knowledge of these genetic alterations has greatly outpaced clinical applications, many new advances are beginning to have an impact on the diagnosis and staging of breast cancer. Clinical evaluation of estrogen and progesterone receptors and HER2/neu status has become routine. The increasing use of these and other molecular markers promises to help refine diagnoses, define disease subsets, and provide more accurate information about the probable biologic outcome of a given tumor. Studies of molecular markers are also likely to lead to the identification and development of new therapeutic targets. I review the molecular markers currently used in the clinical diagnosis and staging of breast cancer, and discuss other potentially useful markers and assays.
Dillon
Deborah A
DA
Department of Pathology, Yale University School of Medicine, New Haven, CT 06520-8023, USA. deborah.dillon@yale.edu
D014408:Biomarkers, Tumor / Q000032:analysis; D001853:Bone Marrow / Q000737:chemistry / Q000473:pathology; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D005819:Genetic Markers; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008198:Lymph Nodes / Q000737:chemistry / Q000473:pathology; D009367:Neoplasm Staging; D011003:Ploidies; D011379:Prognosis
D014408:Biomarkers, Tumor; D005819:Genetic Markers